Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.05 EUR | -1.63% | -1.60% | -6.82% |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 42.79 and 12.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.82% | 607M | - | ||
+4.86% | 104B | A- | ||
-10.06% | 60.79B | A- | ||
+64.76% | 51.13B | B | ||
+14.74% | 38.21B | B | ||
-0.02% | 30.75B | A- | ||
+11.82% | 19.83B | B- | ||
+10.49% | 16.5B | C+ | ||
+7.90% | 13.82B | B- | ||
-4.54% | 13.33B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3101 Stock
- TO7 Stock
- Ratings Toyobo Co., Ltd.